Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPENASDAQ:ARDSNASDAQ:EFTRNASDAQ:EVLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.00$0.00▼$0.45$3K3.9435 shs1 shsARDSAridis Pharmaceuticals$0.00+50.0%$0.00$0.00▼$0.08$16K12.428,041 shs1,300 shsEFTReFFECTOR Therapeutics$0.00-95.0%$0.00$0.00▼$1.74N/A0.422,826 shs14,076 shsEVLOEvelo Biosciences$0.00-20.0%$0.00$0.00▼$0.06$8K0.7710,980 shs4,282 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+275.00%+400.00%-98.57%ARDSAridis Pharmaceuticals0.00%+50.00%+200.00%+200.00%-99.47%EFTReFFECTOR Therapeutics-95.00%-50.00%-50.00%-50.00%-99.99%EVLOEvelo Biosciences0.00%-20.00%-20.00%-84.00%-33.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/AARDSAridis Pharmaceuticals 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AARDSAridis Pharmaceuticals$3.09M0.01N/AN/AN/A∞EFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/AARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%ARDSAridis Pharmaceuticals9.65%EFTReFFECTOR Therapeutics57.67%EVLOEvelo Biosciences0.31%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%ARDSAridis Pharmaceuticals5.50%EFTReFFECTOR Therapeutics4.70%EVLOEvelo Biosciences1.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataEVLOEvelo Biosciences12018.98 million18.79 millionNo DataAMPE, ARDS, EFTR, and EVLO HeadlinesRecent News About These CompaniesEvelo's Compass E-Trike Has Comfort, Range, and Even Power; Priced Decently Well, TooApril 17, 2025 | autoevolution.comEvelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comEvelo Biosciences, Inc. (EVLO)August 24, 2024 | nz.finance.yahoo.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportFebruary 22, 2024 | benzinga.comEvelo Biosciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingDecember 6, 2023 | cbonds.comEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 24, 2023 | msn.comEvelo Bio Shutdown Follows a Series of Microbiome Therapy Trial FailuresNovember 23, 2023 | medcitynews.comFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 22, 2023 | bizjournals.comEvelo’s voyage ends, as Flagship-founded biotech finds dissolution is only viable optionNovember 22, 2023 | fiercebiotech.comFMR LLC Reduces Stake in Evelo Biosciences IncNovember 14, 2023 | finance.yahoo.comEvelo Biosciences Inc EVLONovember 10, 2023 | morningstar.comPresident & CEO GILL SIMBA sale 1,996 shares of Evelo Biosciences Inc [EVLO]November 3, 2023 | knoxdaily.comQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20November 1, 2023 | msn.comEVLO shares expected to outperform in the next 12 monthsOctober 26, 2023 | knoxdaily.comTD Cowen Downgrades Evelo Biosciences (EVLO)October 19, 2023 | msn.comRecent Insider Activity Could Benefit Evelo Biosciences Inc (EVLO)October 18, 2023 | knoxdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumJoby's Q1: Key Milestones Achieved as Path to Market CrystalizesBy Jeffrey Neal Johnson | May 8, 2025View Joby's Q1: Key Milestones Achieved as Path to Market CrystalizesWaste Management Stock: Tariff Proof, But Overbought?By Chris Markoch | May 2, 2025View Waste Management Stock: Tariff Proof, But Overbought?AMPE, ARDS, EFTR, and EVLO Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0030 0.00 (0.00%) As of 05/28/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Aridis Pharmaceuticals NASDAQ:ARDS$0.0003 +0.00 (+50.00%) As of 05/29/2025 03:53 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.eFFECTOR Therapeutics NASDAQ:EFTR$0.0001 0.00 (-95.00%) As of 05/29/2025 03:18 PM EasterneFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Evelo Biosciences NASDAQ:EVLO$0.0004 0.00 (-20.00%) As of 05/23/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
